A rodent model of b4galt1-mediated functions
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsGiusy Della Gatta, Qing Fang, Alan Shuldiner
Life of this patent
Estimating the term…
Abstract
This disclosure relates to genetically modified animals. More specifically, this disclosure relates to rodent animals in which an endogenous B4galt1 gene has been modified, e.g., to introduce a mutation that encodes an Asn to Ser substitution in the encoded B4galt1 protein at a position corresponding to position 352 in a human B4GALT1 protein, or to introduce a loss of function mutation (e.g., in a select tissue such as the liver). This disclosure also relates to use of such rodent animals in elucidating the role of B4galt1 in lipid metabolism.
Claims24
A rodent, comprising a modification in an endogenous rodent p4 galactotransferase 1 (B4galt1) gene at an endogenous rodent B4galt1 locus.
An isolated rodent cell or tissue, comprising a modification in an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus.
-21. (canceled)
A method of making a genetically modified rodent, comprising
- (i) introducing a modification into an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus of a rodent embryonic stem (ES) cell, thereby obtaining a modified rodent ES cell comprising a modified rodent B4galt1 gene;
- and
- (ii) making the genetically modified rodent using the modified rodent ES cell.
-33. (canceled)
A method of making a genetically modified rodent, comprising introducing a modification into an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus in a rodent tissue, thereby obtaining the genetically modified rodent.
-41. (canceled)
-46. (canceled)
Dependencies are inferred from the claim text.